Literature DB >> 12695749

Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale.

Vesa Karttunen1, Leena Hiltunen, Vesa Rasi, Elina Vahtera, Matti Hillbom.   

Abstract

The role of paradoxical embolism through patent foramen ovale as a mechanism of cryptogenic stroke is controversial. If a venous source of emboli is relevant, prothrombotic states should be associated with patent foramen ovale and cryptogenic stroke. We assessed the occurrence of several prothrombotic states (factor V Leiden, prothrombin G20210A, deficiencies in protein S, protein C and antithrombin, lupus anticoagulant, anticardiolipin antibodies, elevated factor VIII, resistance to activated protein C) and classical risk factors for venous thrombosis in 57 adult patients with cryptogenic stroke and patent foramen ovale and in 104 matched controls. Prothrombotic states [odds ratio (OR) 2.8; 95% confidence interval (CI), 1.2-6.5; P = 0.021], migraine with aura (OR 4.4; 95% CI 1.8-10.8; P = 0.001) and classical risk factors for venous thrombosis (OR 2.5; 95% CI 1.1-5.7; P = 0.037) were independent risk factors for cryptogenic stroke. In particular factor V Leiden or prothrombin G20210A associated with cryptogenic stroke (P = 0.022) whereas other coagulation abnormalities did not (P = 0.140). Among the patients with prothrombotic states, Valsalva manoeuvre was common at onset of stroke. Our results support the possibility of paradoxical embolism behind strokes in patients with patent foramen ovale.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695749     DOI: 10.1097/01.mbc.0000061288.28953.c8

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  24 in total

1.  Thrombophilia in ischemic stroke subtypes: implications for treatment.

Authors:  Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

Review 2.  Factoring in Factor VIII With Acute Ischemic Stroke.

Authors:  James E Siegler; Alyana Samai; Karen C Albright; Amelia K Boehme; Sheryl Martin-Schild
Journal:  Clin Appl Thromb Hemost       Date:  2015-02-10       Impact factor: 2.389

Review 3.  Haematology and neurology.

Authors:  Steven Austin; Hannah Cohen; Nick Losseff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

Review 4.  Cryptogenic stroke in patients with patent foramen ovale.

Authors:  Jeffrey L Saver
Journal:  Curr Atheroscler Rep       Date:  2007-10       Impact factor: 5.113

Review 5.  Causes of death among persons who survive an acute ischemic stroke.

Authors:  Shuai Zhang; Wen-Bin He; Nai-Hong Chen
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

Review 6.  Patent foramen ovale and stroke.

Authors:  Shunichi Homma; Marco R Di Tullio
Journal:  J Cardiol       Date:  2010-06-29       Impact factor: 3.159

7.  Cerebrovascular Events Secondary to Pulmonary Arteriovenous Malformation Based on Genetic Heterogeneity.

Authors:  Güner Çelik; Hüseyin Yurdakul; Erkan Yildirim
Journal:  Noro Psikiyatr Ars       Date:  2016-09-20       Impact factor: 1.339

Review 8.  The brain's heart - therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease.

Authors:  Mingming Ning; Eng H Lo; Pei-Chen Ning; Su-Yu Xu; David McMullin; Zareh Demirjian; Ignacio Inglessis; G William Dec; Igor Palacios; Ferdinando S Buonanno
Journal:  Pharmacol Ther       Date:  2013-03-23       Impact factor: 12.310

Review 9.  Patent foramen ovale and stroke: what should be done?

Authors:  Marco R Di Tullio; Shunichi Homma
Journal:  Curr Opin Hematol       Date:  2009-09       Impact factor: 3.284

10.  Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study.

Authors:  Kumar Rajamani; Seemant Chaturvedi; Zhezhen Jin; Shunichi Homma; Robin L Brey; Barbara C Tilley; Ralph L Sacco; J L P Thompson; J P Mohr; Steven R Levine
Journal:  Stroke       Date:  2009-06-04       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.